Q-Line Biotech Limited

Annexure II

RESTATED CONSOLIDATED STATEMENT OF PROFIT AND LOSS

(Amount in Rs. Lakhs, except per share Data)

<table><thead><tr><th rowspan="2">PARTICULARS</th><th rowspan="2"></th><th rowspan="2"></th><th colspan="3">For the Year ended on</th></tr><tr><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td>1</td><td>Revenue From Operation</td><td>O</td><td>31,378.04</td><td>20,364.61</td><td>18,273.63</td></tr><tr><td>2</td><td>Other Income</td><td>P</td><td>880.38</td><td>280.20</td><td>207.52</td></tr><tr><td>3</td><td>Total Income (1+2)</td><td></td><td>32,258.42</td><td>20,644.81</td><td>18,481.15</td></tr><tr><td>4</td><td>Expenditure</td><td></td><td></td><td></td><td></td></tr><tr><td>(a)</td><td>Cost of Material Consumed</td><td>Q</td><td>5,762.05</td><td>1,634.74</td><td>908.03</td></tr><tr><td>(b)</td><td>Purchases of Stock-in trade</td><td></td><td>6,372.75</td><td>10,468.19</td><td>8,387.09</td></tr><tr><td>(c)</td><td>Changes in inventories of Stock in trade, WIP & Finished Goods</td><td>R</td><td>2,432.18</td><td>(2,800.98)</td><td>(448.57)</td></tr><tr><td>(d)</td><td>Employee Benefit Expenses</td><td>S</td><td>3,031.59</td><td>2,348.63</td><td>2,368.26</td></tr><tr><td>(e)</td><td>Finance Cost</td><td>T</td><td>1,470.00</td><td>627.52</td><td>379.60</td></tr><tr><td>(f)</td><td>Depreciation and Amortisation Expenses</td><td>U</td><td>732.12</td><td>392.77</td><td>213.75</td></tr><tr><td>(g)</td><td>Other Expenses</td><td>V</td><td>6,341.96</td><td>4,913.78</td><td>3,688.99</td></tr><tr><td>5</td><td>Total Expenditure 4(a) to 4(g)</td><td></td><td>26,142.66</td><td>17,584.65</td><td>15,497.15</td></tr><tr><td>6</td><td>Profit/(Loss) Before Exceptional & extraordinary items & Tax (3-5)</td><td></td><td>6,115.75</td><td>3,060.17</td><td>2,984.01</td></tr><tr><td>7</td><td>Extra-Ordinary Item</td><td></td><td>1,696.52</td><td>-</td><td>-</td></tr><tr><td>8</td><td>Profit/(Loss) Before Tax (6-7)</td><td></td><td>4,419.23</td><td>3,060.17</td><td>2,984.01</td></tr><tr><td>9</td><td>Tax Expense:</td><td></td><td></td><td></td><td></td></tr><tr><td>(a)</td><td>Tax Expense for Current Year</td><td></td><td>2,008.17</td><td>883.01</td><td>858.16</td></tr><tr><td>(b)</td><td>Short/(Excess) Provision of Earlier Year</td><td></td><td>-</td><td>-</td><td>-</td></tr><tr><td>(c)</td><td>Deferred Tax</td><td></td><td>(40.31)</td><td>12.95</td><td>(12.40)</td></tr><tr><td></td><td>Net Current Tax Expenses</td><td></td><td>1,967.86</td><td>895.96</td><td>845.76</td></tr><tr><td>10</td><td>Share of Profit(Loss) of- Associates</td><td></td><td>361.71</td><td>1,280.26</td><td>1,071.46</td></tr><tr><td></td><td></td><td></td><td>361.71</td><td>1,280.26</td><td>1,071.46</td></tr><tr><td>12</td><td>Profit/(Loss) for the Year (8-9+10)</td><td></td><td>2,813.09</td><td>3,444.47</td><td>3,209.71</td></tr><tr><td>13</td><td>Profit/(Loss) attributable to Minority Interest</td><td></td><td>-</td><td>(0.45)</td><td>-</td></tr><tr><td>14</td><td>Profit attributable to Parent Equity Shareholders (12-13)</td><td></td><td>2,813.09</td><td>3,444.92</td><td>3,209.71</td></tr><tr><td>15</td><td>Earnings per equity shares (Face Value of Rs. 10 each)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Basic/Diluted (In Rs.) before extra ordinary items</td><td></td><td>28.63</td><td>21.87</td><td>20.38</td></tr></tbody></table>

The accompanying summary of significant accounting policies, restated consolidated notes to accounts and notes on adjustments for restated consolidated financial Statement (Annexure IV & V, Annexure W to AC) are an integral part of this statement.

As per our consolidated report of even date

For R K Jagetiya & Co
Chartered Accountants
FRN 146264W

FOR AND ON BEHALF OF THE BOARD
Q- Line Biotech Limited

Saurabh Garg
Managing Director & CHAIRMAN
DIN: 02891621

Amita Garg
Whole-Time Director
DIN: 02891610

184